328 related articles for article (PubMed ID: 32293820)
1. The impact of letrozole administration on oocyte morphology in breast cancer patients undergoing fertility preservation.
Bercaire LMN; Cavagna M; Donadio NF; Rocha AR; Portela R; Alves VR; Santos TBB; Cavagna F; Dzik A; Gebrim LH; Nahas EAP
JBRA Assist Reprod; 2020 Jul; 24(3):257-264. PubMed ID: 32293820
[TBL] [Abstract][Full Text] [Related]
2. Response to ovarian stimulation in patients facing gonadotoxic therapy.
Johnson LN; Dillon KE; Sammel MD; Efymow BL; Mainigi MA; Dokras A; Gracia CR
Reprod Biomed Online; 2013 Apr; 26(4):337-44. PubMed ID: 23415997
[TBL] [Abstract][Full Text] [Related]
3. Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients.
Shulman Y; Almog B; Kalma Y; Fouks Y; Azem F; Cohen Y
J Assist Reprod Genet; 2021 Mar; 38(3):743-750. PubMed ID: 33409757
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†.
Pereira N; Hancock K; Cordeiro CN; Lekovich JP; Schattman GL; Rosenwaks Z
Gynecol Endocrinol; 2016 Oct; 32(10):823-826. PubMed ID: 27114051
[TBL] [Abstract][Full Text] [Related]
5. Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial.
Letourneau J; Juarez-Hernandez F; Wald K; Ribeiro S; Wang A; McCulloch CE; Mok-Lin E; Dolezal M; Chien AJ; Cedars MI; Rosen M
J Assist Reprod Genet; 2021 Sep; 38(9):2455-2463. PubMed ID: 34312774
[TBL] [Abstract][Full Text] [Related]
6. Effect of letrozole added to gonadotropins in controlled ovarian stimulation protocols on the yield and maturity of retrieved oocytes.
Ben-Haroush A; Wertheimer A; Klochendler E; Sapir O; Shufaro Y; Oron G
Gynecol Endocrinol; 2019 Apr; 35(4):324-327. PubMed ID: 30596311
[TBL] [Abstract][Full Text] [Related]
7. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of random-start controlled ovarian stimulation in cancer patients.
Kim JH; Kim SK; Lee HJ; Lee JR; Jee BC; Suh CS; Kim SH
J Korean Med Sci; 2015 Mar; 30(3):290-5. PubMed ID: 25729252
[TBL] [Abstract][Full Text] [Related]
9. Controlled ovarian stimulation outcomes of fertility preservation procedures in newly diagnosed breast cancer patients: a retrospective study from a single-tertiary-IVF centre.
Sahin G; Goker ENT; Gokmen E; Yeniay L; Acet F; Zekioglu O; Tavmergen E
J Obstet Gynaecol; 2022 Apr; 42(3):518-523. PubMed ID: 34382483
[TBL] [Abstract][Full Text] [Related]
10. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation.
Cakmak H; Katz A; Cedars MI; Rosen MP
Fertil Steril; 2013 Dec; 100(6):1673-80. PubMed ID: 23987516
[TBL] [Abstract][Full Text] [Related]
11. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients.
Turan V; Bedoschi G; Moy F; Oktay K
Fertil Steril; 2013 Dec; 100(6):1681-5.e1. PubMed ID: 24055050
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
13. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers.
Goldrat O; Van Den Steen G; Gonzalez-Merino E; Dechène J; Gervy C; Delbaere A; Devreker F; De Maertelaer V; Demeestere I
Reprod Biol Endocrinol; 2019 Jan; 17(1):3. PubMed ID: 30606204
[TBL] [Abstract][Full Text] [Related]
14. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
[TBL] [Abstract][Full Text] [Related]
15. Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy.
Danis RB; Pereira N; Elias RT
Curr Pharm Biotechnol; 2017 Nov; 18(8):609-613. PubMed ID: 28786354
[TBL] [Abstract][Full Text] [Related]
16. [Fertility preserving methods in women with breast cancer before gonadotoxic therapy].
Halászová N; Crha I; Huser M; Weinberger V; Žáková J; Ješeta M; Lousová E; Filipinská E; Ventruba P
Ceska Gynekol; 2017; 82(4):287-292. PubMed ID: 28925272
[TBL] [Abstract][Full Text] [Related]
17. Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response.
Volodarsky-Perel A; Cohen Y; Arab S; Son WY; Suarthana E; Dahan MH; Tulandi T; Buckett W
Hum Reprod; 2019 Mar; 34(3):530-538. PubMed ID: 30689898
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
19. Assessing ovarian stimulation with letrozole and levonorgestrel intrauterine system after combined fertility-sparing approach for atypical endometrial lesions: a retrospective case-control study.
Gallo A; Di Spiezio Sardo A; Conforti A; Iorio GG; Zizolfi B; Buonfantino C; De Angelis MC; Strina I; Marrone V; Bifulco G; Alviggi C
Reprod Biomed Online; 2024 May; 48(5):103750. PubMed ID: 38430660
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
